Recurrent amplification of RTEL1 and ABCA13 and its synergistic effect associated with clinicopathological data of gastric adenocarcinoma

Table 1 Clinicopathological data of patients with and without RTEL1 and ABCA13 amplification

	RTEL1 CNV		p-value	ABCA13 CNV		p-value	RTEL1 and ABCA13 amplification		p-value
	≥3 copies	Others		≥3 copies	Others		Present	Absent
Gender
Male	32	53	0.987	38	42	0.003*	17	61	0.031*
Female	15	25		7	30		2	34
Age
≤50 years	8	27	0.034*	10	21	0.408	2	29	0.074
>50 years	39	51		35	51		17	66
Histopathology
Intestinal	36	46	0.045*	34	43	0.079	15	61	0.214
Diffuse	11	32		11	29		4	34
Localization
Cardia	12	12	0.197	9	15	0.901	4	19	0.969
Non-cardia	35	63		35	55		15	73
Stage
I–II	17	37	0.218	16	34	0.215	4	43	0.05*
III–IV	30	41		29	38		15	52
pN
N0	9	19	0.395	5	19	0.033*	2	23	0.157
N1 or more	37	53		39	48		17	67
pT
T1–T3	34	62	0.359	36	53	0.431	13	74	0.375
T4	13	16		9	19		6	21
pM
M0	10	15	0.746	10	13	0.741	4	17	0.360
M1	12	15		13	14		8	18

M male, F female, pN lymph node metastasis status, N0 without lymph node metastasis, N1 or more metastasis in one ore more lymph nodes, pT extent of the primary tumor, T1–T3 without serosal extravasation, T4 with serosal extravasation, pM, distant metastasis status, M1 with distant metastasis, M0 without distant metastasis. *Significant difference between groups with and without amplification, p ≤ 0.05, Chi-square test

ISSN: 1755-8166